Literature DB >> 77662

Burn unit management of toxic epidermal necrolysis.

R H Demling, S Ellerbe, N J Lowe.   

Abstract

Toxic epidermal necrolysis is the name given to a group of dermatologic disorders characterized by a separation of epidermis and dermis with a subsequent skin slough. The denuded areas have the appearance of a second-degree burn. The complications of infection, negative nitrogen balance, severe pain, and emotional instability are identical to those seen in the patient with major burns. There are difficulties in patient management and advantages in burn unit care. As with the major burn, care of the patient with skin loss from toxic epidermal necrolysis is extremely complex, requiring the expertise of a burn team along with that of the dermatologist.

Entities:  

Mesh:

Year:  1978        PMID: 77662     DOI: 10.1001/archsurg.1978.01370180100019

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  6 in total

Review 1.  Stevens-Johnson syndrome: a review of the literature.

Authors:  V J Stitt
Journal:  J Natl Med Assoc       Date:  1988-01       Impact factor: 1.798

2.  Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids.

Authors:  P H Halebian; V J Corder; M R Madden; J L Finklestein; G T Shires
Journal:  Ann Surg       Date:  1986-11       Impact factor: 12.969

3.  Esophageal stricture secondary to drug-induced toxic epidermal necrolysis.

Authors:  T E Herman; D C Kushner; R H Cleveland
Journal:  Pediatr Radiol       Date:  1984

4.  Patients with acute skin loss: are they best managed on a burns unit?

Authors:  S Hettiaratchy; D Moloney; J Clarke
Journal:  Ann R Coll Surg Engl       Date:  2001-01       Impact factor: 1.891

Review 5.  Clinical features and management of severe dermatological reactions to drugs.

Authors:  M C Raviglione; A Pablos-Mendez; R Battan
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

6.  'Skin failure'--a real entity: discussion paper.

Authors:  C Irvine
Journal:  J R Soc Med       Date:  1991-07       Impact factor: 18.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.